↓ Skip to main content

Dove Medical Press

Article Metrics

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update

Overview of attention for article published in Clinical Ophthalmology, November 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
26 Mendeley
Title
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
Published in
Clinical Ophthalmology, November 2017
DOI 10.2147/opth.s145732
Pubmed ID
Authors

Praveen Patel, Helen Devonport, Sobha Sivaprasad, Adam H Ross, Gavin Walters, Richard P Gale, Andrew J Lotery, Sajjad Mahmood, James S Talks, Jackie Napier

Abstract

National recommendations on continued administration of aflibercept solution for injection after the first year of treatment for neovascular age-related macular degeneration (nAMD) have been developed by an expert panel of UK retina specialists, based on clinician experience and treatment outcomes seen in year 2. The 2017 update reiterates that the treatment goal is to maintain or improve the macular structural and functional gains achieved in year 1 while attempting to reduce or minimize the treatment burden, recognizing the need for ongoing treatment. At the end of year 1 (ie, the decision visit at month 11), two treatment options should be considered: do not extend the treatment interval and maintain fixed 8-weekly dosing, or extend the treatment interval using a treat-and-extend regimen up to a maximum 12 weeks. Criteria for considering not extending the treatment interval are persistent macular fluid with stable vision, recurrent fluid, decrease in vision in the presence of fluid, macular hemorrhage, new choroidal neovascularization or any other sign(s) of exudative disease activity considered vision threatening in the opinion of the treating clinician. Treatment extension is recommended for eyes with a dry macula (ie, without macular fluid) and stable vision. Under both options, the treatment interval may be shortened if visual and/or anatomic outcomes deteriorate. Monitoring without treatment may be considered for eyes with a fluid-free macula for a minimum duration of 48 weeks. A patient completing one full year of monitoring without requiring injections may be considered for discharge from clinic. The treatment algorithm incorporates return to fixed 8-weekly dosing for disease reactivation during treatment extension and reinstatement of treatment for disease recurrence following discontinuation or discharge. For bilateral nAMD, either the eye requiring the more intensive treatment or the eye with the better vision, guided by local clinical practice, should determine the retreatment schedule overall.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 19%
Other 3 12%
Student > Bachelor 3 12%
Unspecified 1 4%
Student > Doctoral Student 1 4%
Other 6 23%
Unknown 7 27%
Readers by discipline Count As %
Medicine and Dentistry 9 35%
Pharmacology, Toxicology and Pharmaceutical Science 4 15%
Unspecified 1 4%
Nursing and Health Professions 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 2 8%
Unknown 8 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2017.
All research outputs
#11,106,134
of 12,488,808 outputs
Outputs from Clinical Ophthalmology
#1,436
of 1,597 outputs
Outputs of similar age
#318,501
of 379,473 outputs
Outputs of similar age from Clinical Ophthalmology
#30
of 38 outputs
Altmetric has tracked 12,488,808 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,597 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 379,473 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.